AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

U.S. infectious disease expert Anthony Fauci said on Wednesday that AstraZeneca's decision to pause global trials of its ...

Full results from the NATRON Phase III trial showed AstraZeneca’s (AZN) Fasenra demonstrated a statistically significant delay in the time to ...

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

A former professional poker player for 15 years, Roy Bhasin — known as Zeneca in crypto — grew a huge following on X as the spreadsheet guy who tracked daily floor prices of NFTs during the 2021 mania ...